Vanguard Capital Management
CATX icon

Vanguard Capital Management’s Perspective Therapeutics CATX Stock Holding History

Vanguard Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Buy
4,436,572
+57,616
+1% +$218K ﹤0.01% 2594
2026
Q1 		$18.3M Buy
+4,378,956
New +$18.5M ﹤0.01% 2396

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management's CATX Position: Q2 2026 in Review

Vanguard Capital Management increased its Perspective Therapeutics (CATX) stake by 1.3% in Q2 2026, buying an estimated $218K and bringing the position to 4,436,572 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2594.

Vanguard Capital Management first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. The position peaked at $18.3M in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Vanguard Capital Management held 4,436,572 shares of Perspective Therapeutics worth $15.1M as of Q2 2026.
  • Vanguard Capital Management bought 57,616 Perspective Therapeutics shares in Q2 2026, an estimated $218K.
  • Perspective Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2594 holding.
  • Vanguard Capital Management first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Perspective Therapeutics position peaked at $18.3M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.